{"id":22477,"date":"2026-10-30T12:05:32","date_gmt":"2026-10-30T11:05:32","guid":{"rendered":"https:\/\/www.gvperte.it\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/"},"modified":"2026-11-02T14:17:21","modified_gmt":"2026-11-02T13:17:21","slug":"defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer","status":"publish","type":"post","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/","title":{"rendered":"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"

It is not a vaccine to prevent cancer, but to teach the immune system to better recognize what remains of the disease after surgery. <\/span><\/span><\/span><\/p>\n

The first results of the Phase 3 INTerpath-001 study, published in recent weeks, open a new perspective in the treatment of high-risk melanoma, with therapy built on the characteristics of the individual patient. Looking ahead, we are at a turning point. <\/span><\/span><\/span><\/p>\n

The innovation stems from the encounter between two tools that have changed oncology in recent years: immunotherapy and mRNA technology, the same technology many have come to know during the pandemic. But in this case the goal is very different from that of a traditional vaccine. You don’t try to stop a healthy person from getting sick: instead, you try training their immune defenses to more precisely identify any cancer cells left after surgery. <\/span><\/span><\/p>\n

The study, conducted on over 1,100 patients, involves a personalized mRNA vaccine developed by the U.S. companies Moderna and Merck\/MSD. The results indicate a significant reduction in the risk of recurrence and distant metastases when the vaccine is combined with standard immunotherapy. <\/span><\/span><\/p>\n","protected":false},"author":89,"featured_media":22428,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"give_campaign_id":0,"footnotes":""},"categories":[2007],"tags":[3341,3339,3506,3507,3508],"class_list":["post-22477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-green-salus","tag-cancer","tag-cancers","tag-melanoma","tag-morandi","tag-vaccine"],"acf":{"categoria":[2007],"categoria_source":{"label":"Category","type":"taxonomy","formatted_value":[{"term_id":2007,"name":"Green\/Salus","slug":"green-salus","term_group":0,"term_taxonomy_id":2007,"taxonomy":"category","description":"","parent":0,"count":48,"filter":"raw"}]},"sottotitolo_h2":"A study demonstrates this: personalized mRNA vaccination, combined with immunotherapy, shows promising results in reducing melanoma recurrence and metastasis. Scientific verifications and the approval process remain to be completed, but it is a turning point. Oncologist Paolo Morandi speaks ","sottotitolo_h2_source":{"label":"Subtitle","type":"text","formatted_value":"A study demonstrates this: personalized mRNA vaccination, combined with immunotherapy, shows promising results in reducing melanoma recurrence and metastasis. Scientific verifications and the approval process remain to be completed, but it is a turning point. Oncologist Paolo Morandi speaks "},"immagini_principale":{"ID":22428,"id":22428,"title":"att3 Vaccino personalizzato contro il tumore","filename":"att3-Vaccino-personalizzato-contro-il-tumore.jpg","filesize":423020,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/att3-vaccino-personalizzato-contro-il-tumore-2\/","alt":"","author":"89","description":"","caption":"","name":"att3-vaccino-personalizzato-contro-il-tumore-2","status":"inherit","uploaded_to":22477,"date":"2026-10-30 09:34:35","modified":"2026-11-02 13:17:21","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.gvperte.it\/wp-includes\/images\/media\/default.png","width":1672,"height":941,"sizes":{"thumbnail":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-768x432.jpg","medium-width":768,"medium-height":432,"medium_large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-768x432.jpg","medium_large-width":768,"medium_large-height":432,"large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","large-width":800,"large-height":450,"1536x1536":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-1536x864.jpg","1536x1536-width":1536,"1536x1536-height":864,"2048x2048":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","2048x2048-width":1672,"2048x2048-height":941,"mailpoet_newsletter_max":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-1320x743.jpg","mailpoet_newsletter_max-width":1320,"mailpoet_newsletter_max-height":743}},"immagini_principale_source":{"label":"Main images","type":"image","formatted_value":{"ID":22428,"id":22428,"title":"att3 Vaccino personalizzato contro il tumore","filename":"att3-Vaccino-personalizzato-contro-il-tumore.jpg","filesize":423020,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/att3-vaccino-personalizzato-contro-il-tumore-2\/","alt":"","author":"89","description":"","caption":"","name":"att3-vaccino-personalizzato-contro-il-tumore-2","status":"inherit","uploaded_to":22477,"date":"2026-10-30 09:34:35","modified":"2026-11-02 13:17:21","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.gvperte.it\/wp-includes\/images\/media\/default.png","width":1672,"height":941,"sizes":{"thumbnail":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-768x432.jpg","medium-width":768,"medium-height":432,"medium_large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-768x432.jpg","medium_large-width":768,"medium_large-height":432,"large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","large-width":800,"large-height":450,"1536x1536":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-1536x864.jpg","1536x1536-width":1536,"1536x1536-height":864,"2048x2048":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","2048x2048-width":1672,"2048x2048-height":941,"mailpoet_newsletter_max":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore-1320x743.jpg","mailpoet_newsletter_max-width":1320,"mailpoet_newsletter_max-height":743}}},"introduzione":"It is not a vaccine to prevent cancer, but to teach the immune system to better recognize what remains of the disease after surgery. <\/span><\/span><\/span>\n\nThe first results of the Phase 3 INTerpath-001 study, published in recent weeks, open a new perspective in the treatment of high-risk melanoma, with therapy built on the characteristics of the individual patient. Looking ahead, we are at a turning point. <\/span><\/span><\/span>\n\nThe innovation stems from the encounter between two tools that have changed oncology in recent years: immunotherapy and mRNA technology, the same technology many have come to know during the pandemic. But in this case the goal is very different from that of a traditional vaccine. You don't try to stop a healthy person from getting sick: instead, you try training their immune defenses to more precisely identify any cancer cells left after surgery. <\/span><\/span>\n\nThe study, conducted on over 1,100 patients, involves a personalized mRNA vaccine developed by the U.S. companies Moderna and Merck\/MSD. The results indicate a significant reduction in the risk of recurrence and distant metastases when the vaccine is combined with standard immunotherapy. <\/span><\/span>","introduzione_source":{"label":"Introduction","type":"wysiwyg","formatted_value":"

It is not a vaccine to prevent cancer, but to teach the immune system to better recognize what remains of the disease after surgery. <\/span><\/span><\/span><\/p>\n

The first results of the Phase 3 INTerpath-001 study, published in recent weeks, open a new perspective in the treatment of high-risk melanoma, with therapy built on the characteristics of the individual patient. Looking ahead, we are at a turning point. <\/span><\/span><\/span><\/p>\n

The innovation stems from the encounter between two tools that have changed oncology in recent years: immunotherapy and mRNA technology, the same technology many have come to know during the pandemic. But in this case the goal is very different from that of a traditional vaccine. You don’t try to stop a healthy person from getting sick: instead, you try training their immune defenses to more precisely identify any cancer cells left after surgery. <\/span><\/span><\/p>\n

The study, conducted on over 1,100 patients, involves a personalized mRNA vaccine developed by the U.S. companies Moderna and Merck\/MSD. The results indicate a significant reduction in the risk of recurrence and distant metastases when the vaccine is combined with standard immunotherapy. <\/span><\/span><\/p>\n"},"paragrafi_articolo":[{"titolo_paragrafo":"The promising numbers","testo_paragrafo":"In numbers: if 100 relapses occur among unvaccinated people undergoing immunotherapy, approximately 50-55 of those vaccinated and similarly undergoing immunotherapy are observed. And the benefit is even more evident in preventing the appearance of metastases in distant organs (such as lungs, liver, or brain): the addition of the vaccine has shown a reduction in the risk of distant metastases of approximately 59-62%. This means that more than 6 out of 10 serious metastases that would have formed even years later are blocked by the immune response activated by the personalized vaccine. <\/span><\/span>\n\nPaolo Morandi, former head of Oncology at the Angelo Hospital in Mestre and at the Civil Hospital in Venice of the ULSS 3 Serenissima, invites us to look at the logic behind this new strategy. \u00abThe concept of the vaccine is that everyone is different in terms of disease and the characteristics of their immune system.\u00bb For this reason, therapy is not prepared in the same way for everyone, but seeks to build a specific target for each patient. <\/span><\/span>\n\nThe process starts from two pieces of information: a blood sample and a tumor tissue sample. The latter is analyzed to identify the mutations characteristic of the neoplasm. The algorithms then select up to 34 neoantigens, that is, molecular characteristics specific to that tumor, which can be used to stimulate an immune response. <\/span><\/span>\n\nSimply put, it's as if the immune system is being shown a much more precise identikit of the enemy. The more information the body's defenses are provided \u2013 Morandi emphasizes - the greater the precision with which they recognize the cells to be targeted. <\/span><\/span>\n\nIn fact, mRNA contains the instructions necessary to produce the proteins corresponding to the selected antigens. This information is used by the cells presenting the antigen and then shown to the immune system. There's nothing mysterious about the underlying mechanism, Morandi emphasizes; what's new is the ability to choose in a highly personalized way which tumor characteristics to present to the body's defenses. <\/span><\/span>\n\nThe vaccine is also combined with immunotherapy. The idea is to combine two actions: on the one hand, to make the target more precise, on the other, to remove some of the brakes that prevent the immune system from acting effectively. In the case of the study, the comparison was rigorous: patients were given either vaccine or placebo along with the same immunotherapy, in a double-blind study. <\/span><\/span>","multimedia":"immagine","video":null,"immagine_paragrafo":{"ID":22430,"id":22430,"title":"melanoma vaccino","filename":"melanoma-vaccino.jpg","filesize":237973,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/melanoma-vaccino-2\/","alt":"","author":"89","description":"","caption":"","name":"melanoma-vaccino-2","status":"inherit","uploaded_to":22477,"date":"2026-10-30 09:41:11","modified":"2026-11-02 13:17:21","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.gvperte.it\/wp-includes\/images\/media\/default.png","width":1536,"height":1024,"sizes":{"thumbnail":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-768x512.jpg","medium-width":768,"medium-height":512,"medium_large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-768x512.jpg","medium_large-width":768,"medium_large-height":512,"large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","large-width":800,"large-height":533,"1536x1536":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","1536x1536-width":1536,"1536x1536-height":1024,"2048x2048":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","2048x2048-width":1536,"2048x2048-height":1024,"mailpoet_newsletter_max":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-1320x880.jpg","mailpoet_newsletter_max-width":1320,"mailpoet_newsletter_max-height":880}},"didascalia":""},{"titolo_paragrafo":"And then there remains the memory of the target to be hit","testo_paragrafo":"The results, according to Morandi, are relevant because they do not only show a temporary postponement of the recurrence. The survival curves of the two groups remain separated over time and the available data reach approximately five years. <\/span><\/span>\n\nThe explanation also comes from observing the immune system. In patients treated with the vaccine, the oncologist adds, an expansion of T cells is observed, that is, those immune cells that can recognize the new antigens identified in the tumor. And the data doesn't seem to be limited to the first few weeks: clonal expansion remains observable over time. <\/span><\/span>\n\nThis, according to Morandi, is one of the most interesting aspects of the strategy: the therapy may end, but the immune system seems to maintain a sort of memory of the target. \u00abThis way you can recondition the system longer than the duration of the treatment, which means you can \u201creclamation\u201d the system, regenerate it, stabilize it and there is no need to intervene further\u00bb. <\/span><\/span>\n\nThe data concern patients with high-risk melanoma, particularly stage 3 situations, and patients who have had metastatic disease undergoing treatment. The goal of research, however, is to better understand when to include the vaccine in the disease pathway. <\/span><\/span>\n\nMelanoma currently represents one of the ideal models for testing this strategy, because it is a tumor particularly sensitive to the action of the immune system. \u00abMelanoma itself is a tumor that we can define as \u201chot\u201d from an immunological point of view\u00bb, explains Morandi. The real challenge will therefore be to understand whether the same principle will also work in tumors in which immune defenses are less easily activated. <\/span><\/span>","multimedia":"immagine","video":null,"immagine_paragrafo":{"ID":22432,"id":22432,"title":"melanoma_mrna_vaccine_illustration","filename":"melanoma_mrna_vaccine_illustration.jpg","filesize":379074,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/melanoma_mrna_vaccine_illustration-2\/","alt":"","author":"89","description":"","caption":"","name":"melanoma_mrna_vaccine_illustration-2","status":"inherit","uploaded_to":22477,"date":"2026-10-30 09:45:48","modified":"2026-11-02 13:17:21","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.gvperte.it\/wp-includes\/images\/media\/default.png","width":1376,"height":768,"sizes":{"thumbnail":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-768x429.jpg","medium-width":768,"medium-height":429,"medium_large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-768x429.jpg","medium_large-width":768,"medium_large-height":429,"large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","large-width":800,"large-height":447,"1536x1536":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","1536x1536-width":1376,"1536x1536-height":768,"2048x2048":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","2048x2048-width":1376,"2048x2048-height":768,"mailpoet_newsletter_max":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-1320x737.jpg","mailpoet_newsletter_max-width":1320,"mailpoet_newsletter_max-height":737}},"didascalia":""},{"titolo_paragrafo":"And what about the other organs they will do? ","testo_paragrafo":"Studies are already underway in other malignancies, including lung, kidney, bladder, and pancreatic cancer. \u00abIt will be interesting to try to understand whether the pancreas or lung or other organs give signals of effectiveness of the therapy that are not, I say, overlapping, because that would be too nice, but still consistent with this model.\u00bb <\/span><\/span>\n\nThis is where research could bring about a more general change in the way we think about cancer care: no longer simply choosing a therapy based on the affected organ, but progressively adapting it to the biological characteristics of that specific person's tumor. The vaccine, Morandi observes, represents \u00aba turning point\u00bb precisely because it adds a further level of individualization, simultaneously refining precision and efficacy. <\/span><\/span>\n\nOf course, however, enthusiasm and prudence must proceed together. A therapy built on a patient-by-patient basis poses production, time, and cost challenges. Preparation of the individualised dose currently takes 6 weeks, major financial commitment (the estimated costs of producing a single batch ad personam are now between $100,000 and $200,000 per patient, not counting the cost of the matched immunotherapy) and the challenge will be to make the process sustainable when it has to leave the narrow scope of clinical trials. <\/span><\/span>\n\nThe steps still to be taken. <\/span><\/span>A closed note, however, must be made. Indeed, it should be remembered that quantitative safety and efficacy data have not yet been disclosed, nor have they yet been validated by the medical-scientific community with expertise in the field, nor have they yet been approved by the appropriate regulatory agencies. Furthermore, the actual possibility of implementing the production of customized mRNA vaccines on a large scale remains to be explored, due to time and cost constraints. <\/span><\/span>\n\nOnly then will it be possible to fully assess the extent of this potential breakthrough in the fight against cancer.<\/span><\/span>","multimedia":"immagine","video":null,"immagine_paragrafo":false,"didascalia":""}],"paragrafi_articolo_source":{"label":"Article Paragraphs","type":"repeater","formatted_value":[{"titolo_paragrafo":"The promising numbers","testo_paragrafo":"

In numbers: if 100 relapses occur among unvaccinated people undergoing immunotherapy, approximately 50-55 of those vaccinated and similarly undergoing immunotherapy are observed. And the benefit is even more evident in preventing the appearance of metastases in distant organs (such as lungs, liver, or brain): the addition of the vaccine has shown a reduction in the risk of distant metastases of approximately 59-62%. This means that more than 6 out of 10 serious metastases that would have formed even years later are blocked by the immune response activated by the personalized vaccine. <\/span><\/span><\/p>\n

Paolo Morandi, former head of Oncology at the Angelo Hospital in Mestre and at the Civil Hospital in Venice of the ULSS 3 Serenissima, invites us to look at the logic behind this new strategy. \u00abThe concept of the vaccine is that everyone is different in terms of disease and the characteristics of their immune system.\u00bb For this reason, therapy is not prepared in the same way for everyone, but seeks to build a specific target for each patient. <\/span><\/span><\/p>\n

The process starts from two pieces of information: a blood sample and a tumor tissue sample. The latter is analyzed to identify the mutations characteristic of the neoplasm. The algorithms then select up to 34 neoantigens, that is, molecular characteristics specific to that tumor, which can be used to stimulate an immune response. <\/span><\/span><\/p>\n

Simply put, it’s as if the immune system is being shown a much more precise identikit of the enemy. The more information the body’s defenses are provided \u2013 Morandi emphasizes – the greater the precision with which they recognize the cells to be targeted. <\/span><\/span><\/p>\n

In fact, mRNA contains the instructions necessary to produce the proteins corresponding to the selected antigens. This information is used by the cells presenting the antigen and then shown to the immune system. There’s nothing mysterious about the underlying mechanism, Morandi emphasizes; what’s new is the ability to choose in a highly personalized way which tumor characteristics to present to the body’s defenses. <\/span><\/span><\/p>\n

The vaccine is also combined with immunotherapy. The idea is to combine two actions: on the one hand, to make the target more precise, on the other, to remove some of the brakes that prevent the immune system from acting effectively. In the case of the study, the comparison was rigorous: patients were given either vaccine or placebo along with the same immunotherapy, in a double-blind study. <\/span><\/span><\/p>\n","multimedia":"immagine","video":null,"immagine_paragrafo":{"ID":22430,"id":22430,"title":"melanoma vaccino","filename":"melanoma-vaccino.jpg","filesize":237973,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/melanoma-vaccino-2\/","alt":"","author":"89","description":"","caption":"","name":"melanoma-vaccino-2","status":"inherit","uploaded_to":22477,"date":"2026-10-30 09:41:11","modified":"2026-11-02 13:17:21","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.gvperte.it\/wp-includes\/images\/media\/default.png","width":1536,"height":1024,"sizes":{"thumbnail":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-768x512.jpg","medium-width":768,"medium-height":512,"medium_large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-768x512.jpg","medium_large-width":768,"medium_large-height":512,"large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","large-width":800,"large-height":533,"1536x1536":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","1536x1536-width":1536,"1536x1536-height":1024,"2048x2048":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino.jpg","2048x2048-width":1536,"2048x2048-height":1024,"mailpoet_newsletter_max":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma-vaccino-1320x880.jpg","mailpoet_newsletter_max-width":1320,"mailpoet_newsletter_max-height":880}},"didascalia":""},{"titolo_paragrafo":"And then there remains the memory of the target to be hit","testo_paragrafo":"

The results, according to Morandi, are relevant because they do not only show a temporary postponement of the recurrence. The survival curves of the two groups remain separated over time and the available data reach approximately five years. <\/span><\/span><\/p>\n

The explanation also comes from observing the immune system. In patients treated with the vaccine, the oncologist adds, an expansion of T cells is observed, that is, those immune cells that can recognize the new antigens identified in the tumor. And the data doesn’t seem to be limited to the first few weeks: clonal expansion remains observable over time. <\/span><\/span><\/p>\n

This, according to Morandi, is one of the most interesting aspects of the strategy: the therapy may end, but the immune system seems to maintain a sort of memory of the target. \u00abThis way you can recondition the system longer than the duration of the treatment, which means you can \u201creclamation\u201d the system, regenerate it, stabilize it and there is no need to intervene further\u00bb. <\/span><\/span><\/p>\n

The data concern patients with high-risk melanoma, particularly stage 3 situations, and patients who have had metastatic disease undergoing treatment. The goal of research, however, is to better understand when to include the vaccine in the disease pathway. <\/span><\/span><\/p>\n

Melanoma currently represents one of the ideal models for testing this strategy, because it is a tumor particularly sensitive to the action of the immune system. \u00abMelanoma itself is a tumor that we can define as \u201chot\u201d from an immunological point of view\u00bb, explains Morandi. The real challenge will therefore be to understand whether the same principle will also work in tumors in which immune defenses are less easily activated. <\/span><\/span><\/p>\n","multimedia":"immagine","video":null,"immagine_paragrafo":{"ID":22432,"id":22432,"title":"melanoma_mrna_vaccine_illustration","filename":"melanoma_mrna_vaccine_illustration.jpg","filesize":379074,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","link":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/melanoma_mrna_vaccine_illustration-2\/","alt":"","author":"89","description":"","caption":"","name":"melanoma_mrna_vaccine_illustration-2","status":"inherit","uploaded_to":22477,"date":"2026-10-30 09:45:48","modified":"2026-11-02 13:17:21","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.gvperte.it\/wp-includes\/images\/media\/default.png","width":1376,"height":768,"sizes":{"thumbnail":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-768x429.jpg","medium-width":768,"medium-height":429,"medium_large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-768x429.jpg","medium_large-width":768,"medium_large-height":429,"large":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","large-width":800,"large-height":447,"1536x1536":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","1536x1536-width":1376,"1536x1536-height":768,"2048x2048":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration.jpg","2048x2048-width":1376,"2048x2048-height":768,"mailpoet_newsletter_max":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/melanoma_mrna_vaccine_illustration-1320x737.jpg","mailpoet_newsletter_max-width":1320,"mailpoet_newsletter_max-height":737}},"didascalia":""},{"titolo_paragrafo":"And what about the other organs they will do? ","testo_paragrafo":"

Studies are already underway in other malignancies, including lung, kidney, bladder, and pancreatic cancer. \u00abIt will be interesting to try to understand whether the pancreas or lung or other organs give signals of effectiveness of the therapy that are not, I say, overlapping, because that would be too nice, but still consistent with this model.\u00bb <\/span><\/span><\/p>\n

This is where research could bring about a more general change in the way we think about cancer care: no longer simply choosing a therapy based on the affected organ, but progressively adapting it to the biological characteristics of that specific person’s tumor. The vaccine, Morandi observes, represents \u00aba turning point\u00bb precisely because it adds a further level of individualization, simultaneously refining precision and efficacy. <\/span><\/span><\/p>\n

Of course, however, enthusiasm and prudence must proceed together. A therapy built on a patient-by-patient basis poses production, time, and cost challenges. Preparation of the individualised dose currently takes 6 weeks, major financial commitment (the estimated costs of producing a single batch ad personam are now between $100,000 and $200,000 per patient, not counting the cost of the matched immunotherapy) and the challenge will be to make the process sustainable when it has to leave the narrow scope of clinical trials. <\/span><\/span><\/p>\n

The steps still to be taken. <\/span><\/span>A closed note, however, must be made. Indeed, it should be remembered that quantitative safety and efficacy data have not yet been disclosed, nor have they yet been validated by the medical-scientific community with expertise in the field, nor have they yet been approved by the appropriate regulatory agencies. Furthermore, the actual possibility of implementing the production of customized mRNA vaccines on a large scale remains to be explored, due to time and cost constraints. <\/span><\/span><\/p>\n

Only then will it be possible to fully assess the extent of this potential breakthrough in the fight against cancer.<\/span><\/span><\/p>\n","multimedia":"immagine","video":null,"immagine_paragrafo":false,"didascalia":""}]},"parole_chiave":[],"parole_chiave_source":{"label":"Keywords.","type":"taxonomy","formatted_value":false},"autore_esterno":"Giorgio Malavasi","autore_esterno_source":{"label":"Autore Esterno","type":"text","formatted_value":"Giorgio Malavasi"}},"yoast_head":"\nDefense Becomes Attack: The Vaccine That Teaches How to Hit Cancer - GVperTe<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer - GVperTe\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"GVperTe\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T11:05:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T13:17:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Giorgio Malavasi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Giorgio Malavasi\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/\"},\"author\":{\"name\":\"Giorgio Malavasi\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#\\\/schema\\\/person\\\/27af76ca7c5c513ae49da3d616f5c7b1\"},\"headline\":\"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer\",\"datePublished\":\"2026-10-30T11:05:32+00:00\",\"dateModified\":\"2026-11-02T13:17:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/\"},\"wordCount\":11,\"publisher\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.gvperte.it\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/att3-Vaccino-personalizzato-contro-il-tumore.jpg\",\"keywords\":[\"cancer\",\"cancers\",\"melanoma\",\"Morandi\",\"vaccine\"],\"articleSection\":[\"Green\\\/Salus\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/\",\"url\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/\",\"name\":\"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer - GVperTe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.gvperte.it\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/att3-Vaccino-personalizzato-contro-il-tumore.jpg\",\"datePublished\":\"2026-10-30T11:05:32+00:00\",\"dateModified\":\"2026-11-02T13:17:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.gvperte.it\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/att3-Vaccino-personalizzato-contro-il-tumore.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gvperte.it\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/att3-Vaccino-personalizzato-contro-il-tumore.jpg\",\"width\":1672,\"height\":941},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/\",\"name\":\"GVperTe\",\"description\":\"Notizie e storie, da Venezia e dal Veneto in esclusiva per te\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#organization\",\"name\":\"C.I.D. s.r.l. Societ\u00e0 a Socio Unico\",\"alternateName\":\"C.I.D.\",\"url\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.gvperte.it\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Logo-GV-per-te.png\",\"contentUrl\":\"https:\\\/\\\/www.gvperte.it\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Logo-GV-per-te.png\",\"width\":454,\"height\":397,\"caption\":\"C.I.D. s.r.l. Societ\u00e0 a Socio Unico\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/#\\\/schema\\\/person\\\/27af76ca7c5c513ae49da3d616f5c7b1\",\"name\":\"Giorgio Malavasi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d14ae4f691b1b1e71ae7ea73018081e0926360506f4f06b5a3bc42ef25dcaa?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d14ae4f691b1b1e71ae7ea73018081e0926360506f4f06b5a3bc42ef25dcaa?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d14ae4f691b1b1e71ae7ea73018081e0926360506f4f06b5a3bc42ef25dcaa?s=96&d=mm&r=g\",\"caption\":\"Giorgio Malavasi\"},\"url\":\"https:\\\/\\\/www.gvperte.it\\\/en\\\/author\\\/giorgio-malavasi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer - GVperTe","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer - GVperTe","og_url":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/","og_site_name":"GVperTe","article_published_time":"2026-10-30T11:05:32+00:00","article_modified_time":"2026-11-02T13:17:21+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","type":"image\/jpeg"}],"author":"Giorgio Malavasi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Giorgio Malavasi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#article","isPartOf":{"@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/"},"author":{"name":"Giorgio Malavasi","@id":"https:\/\/www.gvperte.it\/en\/#\/schema\/person\/27af76ca7c5c513ae49da3d616f5c7b1"},"headline":"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer","datePublished":"2026-10-30T11:05:32+00:00","dateModified":"2026-11-02T13:17:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/"},"wordCount":11,"publisher":{"@id":"https:\/\/www.gvperte.it\/en\/#organization"},"image":{"@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","keywords":["cancer","cancers","melanoma","Morandi","vaccine"],"articleSection":["Green\/Salus"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/","url":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/","name":"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer - GVperTe","isPartOf":{"@id":"https:\/\/www.gvperte.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","datePublished":"2026-10-30T11:05:32+00:00","dateModified":"2026-11-02T13:17:21+00:00","breadcrumb":{"@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#primaryimage","url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","contentUrl":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2026\/10\/att3-Vaccino-personalizzato-contro-il-tumore.jpg","width":1672,"height":941},{"@type":"BreadcrumbList","@id":"https:\/\/www.gvperte.it\/en\/defense-becomes-attack-the-vaccine-that-teaches-how-to-hit-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gvperte.it\/en\/"},{"@type":"ListItem","position":2,"name":"Defense Becomes Attack: The Vaccine That Teaches How to Hit Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.gvperte.it\/en\/#website","url":"https:\/\/www.gvperte.it\/en\/","name":"GVperTe","description":"Notizie e storie, da Venezia e dal Veneto in esclusiva per te","publisher":{"@id":"https:\/\/www.gvperte.it\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gvperte.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.gvperte.it\/en\/#organization","name":"C.I.D. s.r.l. Societ\u00e0 a Socio Unico","alternateName":"C.I.D.","url":"https:\/\/www.gvperte.it\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.gvperte.it\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2023\/06\/Logo-GV-per-te.png","contentUrl":"https:\/\/www.gvperte.it\/wp-content\/uploads\/2023\/06\/Logo-GV-per-te.png","width":454,"height":397,"caption":"C.I.D. s.r.l. Societ\u00e0 a Socio Unico"},"image":{"@id":"https:\/\/www.gvperte.it\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.gvperte.it\/en\/#\/schema\/person\/27af76ca7c5c513ae49da3d616f5c7b1","name":"Giorgio Malavasi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d14ae4f691b1b1e71ae7ea73018081e0926360506f4f06b5a3bc42ef25dcaa?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d14ae4f691b1b1e71ae7ea73018081e0926360506f4f06b5a3bc42ef25dcaa?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d14ae4f691b1b1e71ae7ea73018081e0926360506f4f06b5a3bc42ef25dcaa?s=96&d=mm&r=g","caption":"Giorgio Malavasi"},"url":"https:\/\/www.gvperte.it\/en\/author\/giorgio-malavasi\/"}]}},"_links":{"self":[{"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/posts\/22477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/users\/89"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/comments?post=22477"}],"version-history":[{"count":0,"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/posts\/22477\/revisions"}],"acf:term":[{"embeddable":true,"taxonomy":"category","href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/categories\/2007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/media\/22428"}],"wp:attachment":[{"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/media?parent=22477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/categories?post=22477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gvperte.it\/en\/wp-json\/wp\/v2\/tags?post=22477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}